Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares

Rhea-AI Summary

Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL) has announced the pricing of its public offering of 8,437,500 Class A common shares at US$1.60 per share, aiming to raise US$13.5 million in gross proceeds. The company plans to use the funds to support the clinical development of CardiolRx for treating recurrent pericarditis, as well as for general expenses and working capital. Canaccord Genuity is acting as the sole bookrunner for the offering, which is expected to close around October 10, 2024. The offering is being made under a U.S. registration statement and Canadian short form base shelf prospectus, with a final prospectus supplement to be filed with relevant securities commissions.

Positive

• Raising US$13.5 million in gross proceeds through public offering
• Funds to support clinical development of CardiolRx for recurrent pericarditis treatment
• Offering priced at US$1.60 per share, indicating investor interest

Negative

• Potential dilution of existing shareholders' ownership due to new share issuance
• Additional expenses related to underwriting discounts and offering costs

Insights

Financial Analyst

Cardiol Therapeutics has announced a public offering of 8,437,500 Class A common shares at $1.60 per share, aiming to raise $13.5 million in gross proceeds. This move is significant for the company's financial position and future operations. The pricing at $1.60 per share represents a 17% discount to the previous closing price, which may dilute existing shareholders but provides necessary capital.

The funds will primarily support the clinical development of CardiolRx for recurrent pericarditis treatment, alongside general expenses and working capital. This capital injection is important for advancing their pipeline and potentially reaching key milestones. However, the dilution effect and the discounted pricing might put short-term pressure on the stock.

With a current market cap of $133.5 million, this offering represents about 10% of the company's value. While it strengthens the balance sheet, investors should monitor how efficiently the company utilizes these funds to progress its clinical programs and generate value.

Medical Research Analyst

The focus on CardiolRx for recurrent pericarditis treatment is noteworthy. Recurrent pericarditis is a challenging condition with treatment options, representing a significant unmet medical need. Cardiol's approach using anti-inflammatory and anti-fibrotic therapies could potentially address the underlying mechanisms of the disease.

The additional funding from this offering is critical for advancing clinical trials, which are typically expensive and time-consuming in the pharmaceutical industry. Positive results from these trials could significantly boost Cardiol's profile in the cardiovascular therapeutics space.

However, investors should be aware that drug development carries inherent risks. The success of CardiolRx is not guaranteed and setbacks in clinical trials could negatively impact the company's valuation. The timeline for potential FDA approval and market entry should also be considered in long-term investment decisions.

Oakville, Ontario--(Newsfile Corp. - October 9, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announced today the pricing of its previously announced public offering (the "Offering") of 8,437,500 Class A common shares of the Company (the "Common Shares") at a price to the public of US$1.60 per Common Share for gross proceeds of US$13.5 million before deducting the underwriting discounts and commissions and estimated expenses incurred in connection with the Offering.

The Company intends to use the net proceeds from the Offering to support the clinical development of CardiolRx for the treatment of recurrent pericarditis and for general and administrative expenses, working capital and other expenses.

Canaccord Genuity is acting as the sole bookrunner in connection with the Offering.

The Offering is expected to close on or about October 10, 2024 (the "Closing Date"), subject to the satisfaction of customary closing conditions, including the listing of the Common Shares to be issued under the Offering on the Toronto Stock Exchange (the "TSX") and the Nasdaq Capital Market (the "Nasdaq"), receipt of any required approvals of the TSX and Nasdaq, and the entering into of an underwriting agreement between the Company and the underwriter.

The Offering is being made pursuant to a U.S. registration statement on Form F-10, declared effective by the U.S. Securities and Exchange Commissions (the "SEC") on July 16, 2024 (the "Registration Statement"), and the Company's existing Canadian short form base shelf prospectus (the "Base Prospectus") dated July 12, 2024. A preliminary prospectus supplement relating to the Offering has been filed with the securities commission in all of the provinces and territories of Canada, except Quebec, and with the SEC in the United States, and a final prospectus supplement relating to the Offering (the "Supplement") will be filed with the securities commissions in all of the provinces and territories of Canada, except Quebec, and with the SEC in the United States. The Supplement and accompanying Base Prospectus contain important detailed information about the Offering.

The Supplement and accompanying Base Prospectus can be found on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Copies of the Supplement and accompanying Base Prospectus may also be obtained from Canaccord Genuity LLC, 1 Post Office Square, Suite 3000, Boston, Massachusetts 02109, Attn: Syndicate Department, or by email at prospectus@cgf.com. Prospective investors should read the Supplement and accompanying Base Prospectus and the other documents the Company has filed before making an investment decision.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any province, state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such province, state or jurisdiction.

About Cardiol Therapeutics

Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease.

Cautionary statement regarding forward-looking information:

This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are "forward-looking information". Forward looking information contained herein may include, but is not limited to statements regarding the Offering, whether and when the Offering may close, and the anticipated use of proceeds from the Offering. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission and Canadian securities regulators on April 1, 2024, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements and are encouraged to read the Supplement, the accompanying Base Prospectus and the documents incorporated by reference therein.

For further information, please contact:

Trevor Burns, Investor Relations +1-289-910-0855
trevor.burns@cardiolrx.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/226119

FAQ

What is the purpose of Cardiol Therapeutics' (CRDL) public offering?

Cardiol Therapeutics is conducting a public offering to raise US$13.5 million in gross proceeds to support the clinical development of CardiolRx for treating recurrent pericarditis and for general expenses and working capital.

How many shares is Cardiol Therapeutics (CRDL) offering and at what price?

Cardiol Therapeutics is offering 8,437,500 Class A common shares at a price of US$1.60 per share.

When is the expected closing date for Cardiol Therapeutics' (CRDL) public offering?

The public offering is expected to close on or about October 10, 2024, subject to customary closing conditions.

Who is the bookrunner for Cardiol Therapeutics' (CRDL) public offering?

Canaccord Genuity is acting as the sole bookrunner for Cardiol Therapeutics' public offering.